多肽偶联药物在抗癌方面的研究进展

陈 小静, 刘 祚铭, 王 子豪, 陈 紫盺, 石 欣雨, 王 倩, 林璐 通讯
沈阳药科大学 110016

摘要

目的：多肽偶联药物（Peptide Drug Conjugate，PDC）是一类近年来新兴的抗癌靶向性药物，其结构中的多肽可以特异性识别肿瘤细胞上的靶点，靶向性好、特异性高。目前市面上上市的PDC类药物很少，大多处于可研阶段，很少一部分进入临床试验阶段。本文举例了几种常见的多肽偶联药物，以及多肽偶联药物在人体中与特异性靶点的作用情况。

关键词

多肽偶联药物 EphA2 抗癌靶向药物

参考

[1] Eph Receptor Signaling and EphrinsErika M. Lisabeth, Giulia Falivelli and Elena B. Pasquale Cold Spring Harb Perspect Biol 2013; doi: 10.1101/cshper spect.a009159 [2] EphA2: A promising therapeutic target in breast cancerPing Zhaoa, 1, Dewei Jiangb, 1, Yunchao Huangc, *, Ceshi Chenb, d, e, * [3] Design and Synthesis of Potent Bivalent Peptide Agonists Targetingthe EphA2 ，Receptor Srinivas Duggineni,aSayantan Mitra,bIlaria Lamberto,bXiaofeng Han,aYan Xu,aJing An,aElena B. Pasquale,*,b,cand Ziwei Huang*,a [4] Easty, D.J., Herlyn, M., Bennett, D.C., 1995. Abnormal protein tyrosine kinase geneexpression during melanoma progression and metastasis. Int. J. Cancer 60,129e136 [5] Nemoto, T., Ohashi, K., Akashi, T., Johnson, J.D., Hirokawa, K., 1997. Over-expression of protein tyrosine kinases in human esophageal cancer. Pathobi-ology 65, 195e203. [6] Rosenberg, I.M., G€ oke, M., Kanai, M., Reinecker, H.C., Podolsky, D.K., 1997.Epithelial cell kinase-B61: an autocrine loop modulating intestinal epithelialmigration and barrier function. Am. J. Physiol. 273, G824eG832. [7] Walker-Daniels, J., Coffman, K., Azimi, M., Rhim, J.S., Bostwick, D.G., Snyder, P.,Kerns, B.J., Waters, D.J., Kinch, M.S., 1999. Overexpression of the EphA2tyrosine kinase in prostate cancer. Prostate 41, 275e280. [8] Zelinski, D.P., Zantek, N.D., Stewart, J.C., Irizarry, A.R., Kinch, M.S., 2001. EphA2overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res.61, 2301e2306. [9] Ring-Larsen H. De hepato-renale syndromer [The hepato-renal syndromes]. Ugeskr Laeger. 1980 Apr 7;142(15):950-3. Danish. PMID: 6992372. [10] Demeule M, Charfi C, Currie JC, Larocque A, Zgheib A, Kozelko S, Béliveau R, Marsolais C, Annabi B. TH1902, a new docetaxel-peptide conjugate for the treatment of sortilin-positive triple-negative breast cancer. Cancer Sci. 2021 Jul 27. doi: 10.1111/cas.15086. Epub ahead of print. PMID: 34314556. [11] Gowland C, Berry P, Errington J, Jeffrey P, Bennett G, Godfrey L, Pittman M, Niewiarowski A, Symeonides SN, Veal GJ. Development of a LC-MS/MS method for the quantification of toxic payload DM1 cleaved from BT1718 in a Phase I study. Bioanalysis. 2021 Jan;13(2):101-113. doi: 10.4155/bio-2020-0256. Epub 2021 Jan 26. PMID: 33496610. [12] Das S, Al-Toubah T, El-Haddad G, Strosberg J. 177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2019 Nov;13(11):1023-1031. doi: 10.1080/17474124.2019.1685381. Epub 2019 Oct 30. PMID: 31652074; PMCID: PMC7227421.